Antibiotic options for treating community-acquired MRSA. (Q34593646)

3 August 2017

1 reference

title

Antibiotic options for treating community-acquired MRSA. (English)

1 reference

3 August 2017

J Patrick Powell

1

1 reference

PubMed ID

18588495

3 August 2017

Richard P Wenzel

series ordinal

2

1 reference

3 August 2017

1 June 2008

1 reference

Expert Review of Anti-infective Therapy

3 August 2017

1 reference

3 August 2017

6

1 reference

3 August 2017

3

1 reference

3 August 2017

299-307

1 reference

An Enzyme from Bacteria able to Destroy Penicillin

3 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

“Celbenin” - resistant Staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Methicillin-resistant staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Methicillin-resistant, quinupristin-dalfopristin-resistant Staphylococcus aureus with reduced sensitivity to glycopeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Linezolid resistance in a clinical isolate of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

21 January 2018

STAPHYLOCOCCAL TOXIN.

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Pulsed-field gel electrophoresis typing of oxacillin-resistant Staphylococcus aureus isolates from the United States: establishing a national database

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Complete genome sequence of USA300, an epidemic clone of community-acquired meticillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Five cases of bacterial endocarditis after furunculosis and the ongoing saga of community-acquired methicillin-resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Hospital transmission of community-acquired methicillin-resistant Staphylococcus aureus among postpartum women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Emergence of community-associated methicillin-resistant Staphylococcus aureus USA 300 clone as a cause of health care-associated infections among patients with prosthetic joint infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Daptomycin: a review 4 years after first approval

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Intermediate vancomycin susceptibility in a community-associated MRSA clone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Neutralization of Staphylococcus aureus Panton Valentine leukocidin by intravenous immunoglobulin in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Vaccine protection against Staphylococcus aureus pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Epidemiology and outcomes of community-associated methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Fifteen-year study of the changing epidemiology of methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Comparisons of community-associated methicillin-resistant Staphylococcus aureus (MRSA) and hospital-associated MSRA infections in Sacramento, California

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Clinical and laboratory features of community-associated methicillin-resistant Staphylococcus aureus: is it really new?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

MICROBIOLOGY: Weapons of Microbial Drug Resistance Abound in Soil Flora

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.3.299

21 January 2018

Identifiers

DOI

10.1586/14787210.6.3.299

1 reference

3 August 2017

1 reference

PubMed ID

18588495